Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

Inclusion Criteria: * age \>18 * Assessd as resectable PDAC before surgical procedure * Voluntary to donate tumor samples resected in curative surgery for PDAC * Voluntary to participate in the radiological evaluation, tests of serum tumor markers, and the collection of MRD samples according to the study protocol * ECOG state (PS) grades ≤ 2 * Voluntary to sign informed consent and adhering to the requirements and limitations outlined by lCD and this protocol * Confimed as pancreatic ductal adenocarcinoma by pathology * RO or R1 resection * Clinically evalutated eligible for adjuvant therapy * Tumor tissue samples meet the requirements of whole exome sequencing (WES) Exclusion Criteria: * Preoperative imaging examinations show distant metastasis * Have received neoadjuvant therapy * Have any other active malignancy within 5 years before enrollment, or have any other indolent cancers that did not interfere with the primary cancer assessment in the study without prior approval from the research committee * With other physical or mental conditions that may increase the risk of study participation or (in the investigator's judgment) may make the subject ineligible for study participation, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormalities * Have participated in other interventional or observational clinical studies